Verastem, Inc.
Verastem, Inc. is listed today as Verastem, Inc.: market value, financials and filings are on its company page.
Funding rounds
3 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2020 | $100 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Feb 2014 | $4 M | Private placement after listing | $2 to $10 million | equity, options | SEC | |
| Jul 2012 | $2 M | No. 3 | $2 to $10 million | equity | SEC | |
| Nov 2011 | $20 M | No. 2 | $10 to $50 million | equity | SEC | |
| Jul 2011 | $32 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Verastem, Inc., its revenue in fiscal 2024 came from these product and service lines: Sale of COPIKTRA license and related assets $10 million (100%).
Annual report (SEC XBRL) · Dec 2024
Verastem, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2020).
SEC Form D · Mar 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Mar 2020
Products and services#
No products or services of Verastem, Inc. are on record.
Investors#
12 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Bessemer Venture Partners VII Institutional L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| Bessemer Venture Partners VII L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| BVP VII Special Opportunity Fund LP | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| CHP III LP | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| CHP III Management, L.L.C. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| Deer Management Co. LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| Deer VII & Co. L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| Deer VII & Co. Ltd. | Company | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| Longwood Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| MPM Bioventures V GP LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock (Form 3, 2012) | SEC Form 3 |
| MPM Bioventures V LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock (Form 3, 2012) | SEC Form 3 |
| MPM Bioventures V, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock (Form 3, 2012) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 36 investors.
Largest shareholders today
Institutions holding Verastem, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$77 M7.55%
- RTW Investments, LP$54 M5.33%
- Deep Track Capital, LP$46 M4.56%
- Armistice Capital, LLC$46 M4.54%
- Rosalind Advisors, Inc.$34 M3.36%
- State Street Corp$32 M3.19%
- MPM Bioimpact LLC$31 M3.06%
- Vanguard Capital Management LLC$31 M3.03%
- Foresite Capital Management VI LLC$25 M2.50%
- Stonepine Capital Management, LLC$24 M2.41%
- Opaleye Management Inc.$22 M2.18%
- Vanguard Portfolio Management LLC$21 M2.03%
- Balyasny Asset Management L.P.$19 M1.82%
- Geode Capital Management, LLC$18 M1.73%
- Morgan Stanley$15 M1.52%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Brian Stuglik | Executive officer | Mar 2020 |
| Dan Paterson | Executive officer | Mar 2020 |
| Rob Gagnon | Executive officer | Mar 2020 |
| Christoph K. Westphal | Executive officer | Mar 2014 |
| Dan K. Paterson | Executive officer | Mar 2014 |
| Joanna K. Horobin | Executive officer | Mar 2014 |
| John K. Green | Executive officer | Mar 2014 |
| Jonathan K. Pachter | Executive officer | Mar 2014 |
| Monica K. Singh | Executive officer | Mar 2014 |
| Robert K. Forrester | Executive officer | Mar 2014 |
| Christoph Westphal | Executive officer | Jul 2012 |
| Jonathan Pachter | Executive officer | Jul 2012 |
| Robert Forrester | Executive officer | Jul 2012 |
| Paul Brannelly | Executive officer | Jul 2011 |
| Alison Lawton | Director | Mar 2020 |
| Brian Stuglik | Director | Mar 2020 |
| Bruce Wendel | Director | Mar 2020 |
| Eric Rowinsky | Director | Mar 2020 |
| Gina Consylman | Director | Mar 2020 |
| Michael Kauffman | Director | Mar 2020 |
| Timothy Barberich | Director | Mar 2020 |
| Alison K. Lawton | Director | Mar 2014 |
| Christoph K. Westphal | Director | Mar 2014 |
| Henri K. Termeer | Director | Mar 2014 |
| John K. Clarke | Director | Mar 2014 |
| Louise K. Phanstiel | Director | Mar 2014 |
| Michael K. Kauffman | Director | Mar 2014 |
| Richard Aldrich | Director | Mar 2014 |
| Robert K. Forrester | Director | Mar 2014 |
| Stephen K. Sherwin, M.D. | Director | Mar 2014 |
| Ansbert K. Gadicke | Director | Jul 2012 |
| Christoph Westphal | Director | Jul 2012 |
| Stephen K. Kraus | Director | Jul 2012 |
| Piyush K. Gupta | Director | Jul 2011 |
Went public since 2012. Its SEC number is that of a company listed on a stock exchange.